HomeAboutScientific TeamCode of Good PracticeResearchCOVID-19 TestingCardiac HealthClinical Trial Design & MethodologyHepatologyEthnic and Sex Differences Physiology & Drug ResponsesPublicationsNewsCareersSupportContact

What’s a Rich Text element? (H1)

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

What’s a Rich Text element? (H2)

The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content.

Static and dynamic content editing (H3)

A rich text element can be used with static or dynamic content. For static content, just drop it into any page and begin editing. For dynamic content, add a rich text field to any collection and then connect a rich text element to that field in the settings panel. Voila!

How to customize formatting for each rich text (H4)

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

How to customize formatting for each rich text (H5)

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

How to customize formatting for each rich text (H6)

Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

  • Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
  • Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.
  • Headings, paragraphs, blockquotes, figures, images, and figure captions can all be styled after a class is added to the rich text element using the "When inside of" nested selector system.

Why patient safety is paramount in patient trials

14 May 2021


As medicines become more personalised, drug development processes become more precise. It will soon be common to conduct Phase I trials directly with the target population bypassing the typical trials with healthy volunteers. Not only does this mean that less volunteers are needed in the drug development process, but the development time is reduced - as are the associated costs.

It is important to remain cautious when embarking on a Phase I trial with patients. The long established and robust tool kit that is applied to healthy volunteer trials will not be transferable to patient populations where their medical conditions or co-morbidities may cause them to react differently to medicines, the usual biomarkers no longer apply.

Principal Investigators must use all available, relevant data when conducting the trial. It is crucial to learn from non-clinical data ensuring all known risks are managed before first in human trials commence. Patients must be fully informed of the risks before consenting to participate.

Richmond Research Institute was born out of a partnership with St Georges University of London. The Institute is a not-for-profit organisation dedicated to drug safety research to improve and save lives. Our world-class research aims to explore the usefulness of potential new medicines, assesses the safety of existing medicinal products, provides the scientific insights to improve clinical trial methodologies and strategies for personalised medicines.

Read the New Scientist article in full

Related News

Phase I study confirms cardiac safety of potential alopecia treatment

Here we present the results of our recent work on the cardiac safety of cortexolone 17α-propionate (cortexolone).

Effectiveness of 12-lead ECG versus Holter monitor confirmed in important trial methodology

12-lead resting ECGs are considered essential in clinical trials, but their limitations have led to increasing use of 12-lead Holter monitor devices.

Cardiac safety of nolasiban confirmed in Phase I clinical trial

Here we report our recent work on the cardiac safety of nolasiban.

Back to News